Aggressive Angiomyxoma of the Vagina
Zhu Honglan,Wang Shijun
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132521
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:To the editor: Aggressive angiomyxoma (AA) is a very rare soft tissue tumor which affects mainly the soft tissues of the pelvis and perineum in women. As a slow-growing mesenchymal neoplasm, AA tends to infiltrate locally and recur.1 Here we reported a case of AA of the vagina. The patient was a 36-year-old woman, who presented with a 10 cm× 5 cm×5 cm myxoid, well-circumscribed, rubbery mass arising within the vaginal wall and extending to the perineum. Besides a routine clinical work-up, further examinations including ultrasonography and computed tomography (CT) were performed before the operation to evaluate the extent of the disease and reveal the location, relationship and degree of infiltration between tumor and pelvic organs. The preoperative clinical diagnosis included a vaginal unidentified mass and obturator hernia. Under general anesthesia, a laparoscopic exploration was first performed to find the pelvic peritoneum was intact and there was no hernia. Then the vaginal wall was excised and a complete tumor resection, including local excision of part of the vaginal wall, was carried out. The resected tumor measured 10 cm×5 cm×5 cm and weighed 400 g. The cut surface was soft, gray-pink color and had a diffuse gelatinous appearance (Figure 1). On pathological evaluation, it was reported to be an AA consisting of spindle shaped fibroblasts infiltrating the surrounding adipose tissue but without any mitoses or atypia and many vascular structures, some of which were hyalinised, lying on a myxoid background. Immunohistochemical findings revealed that the tumor was positive for CD34, CD31, and desmin, while it was negative for SMA and S-100. The surgical borders of the specimen were negative for tumor. The follow-up is still ongoing without recurrence at four months.Figure 1.: The gross pathology of the resected tumor.AA is a very rare gynecologic tumor and classified as "tumors of uncertain differentiation" in the latest WHO classification. Since 1983, when its histological characteristics were first described, less than 350 cases have been reported in the literature.1,2 AA presents a strong female predominance, with a female-to-male ratio of approximately 6:1, and often arises from the female pelvis-perineum region. Histologically, the tumor consists of a rather hypocellular population of small, somewhat satellite to fusiform cells with thin cytoplasmic processes. There is also a prominent accompanying vascular component, ranging from tiny capillary-like vessels to larger vessels with distinct smooth muscle cells but with no evidence of anastomosis or arborisation. Commonly, mitoses are not seen but occasional cases may show mild atypia. Despite this innocuous-looking histologic pattern, AA recurs in 70% of patients. Immunohistochemical analyses of the tumor, especially the presence of desmin, smooth muscle actin, muscle specific actin, vimentin, CD34, estrogen and progestin receptors are important for diagnosis. Clinically, it is often mistaken for vulvar abscess, Bartolin's cyst, Gartner's duct cyst, vaginal prolapse, pelvic floor hernia, vaginal mass or polyp, or obturatory and levator hernia. Misdiagnosis is seen in 82% of the cases. If AA is suspected clinically, a CT or MRI of the pelvis may be beneficial in order to delineate the tumor. Surgery is the radical and foremost treatment method for AA. Simó et al3 concluded that wide surgical excision is the basis of curative treatment of AA. However Bai et al2 suggested an individualized operative strategy. They suggested that for smaller and superficial tumors, wide local excision is suitable, while for the larger, deep-seated tumors with clear margins to the adjacent normal tissue, efforts should be made to get complete excision. For those extensively and deeply invading the vital pelvic organs, if complete excision is not feasible or severe surgical injury is predicted, they suggested incomplete resection. It was reported that GnRHa could be used as neoadjuvant treatment to shrink tumors preoperatively or as adjuvant treatment to prevent recurrence postoperatively for three months for the cases with tumors positive for ERs and PRs. Radiotherapy has been used for the repeated recurrent cases with persistent complaints. If the recurrent or residual tumors are minor, stable, and negative for ERs and PRs, a simple follow-up strategy has been recommended.2-4 Honglan Zhu Shijun Wang Department of Gynecology and Obstetrics, People's Hospital, Peking University, Beijing 100044, China (Zhu HL and Wang SJ) Correspondence to: Wang Shijun, Department of Gynecology and Obstetrics, People's Hospital, Peking University, Beijing 100044, China (Fax: 86-10-88324710. Email: [email protected]) Conflicts of interests: None.